United States: Deciphering The Final AMP Rule – Key Provisions Impacting Pharmacies, PBMs, And Manufacturers

In late January, the Centers for Medicare & Medicaid Services ("CMS") released the much anticipated Covered Outpatient Drugs Final Rule with Comment (the "AMP Final Rule"). The rule creates the regulatory definition for Average Manufacturer Price ("AMP") and further refines how pharmaceutical manufacturers must calculate Medicaid drug rebates in the wake of the Affordable Care Act ("ACA") and recent health care reform measures. The AMP Final Rule is effective April 1, 2016 and requires prospective compliance, although a limited number of provisions have been delayed until April 2017. Given this compliance date, manufacturers, states, and pharmacies have a limited amount of time to fully analyze and implement the provisions of the rule.

This advisory focuses on four key provisions of the AMP Final Rule that are likely to significantly impact pharmacies, pharmacy benefit managers, and manufacturers: (i) the definition of bona fide service fees; (ii) the definition of bundled sales; (iii) the definition of retail community pharmacy; and (iv) the change in Medicaid reimbursement to reimbursement based on Actual Acquisition Cost ("AAC").

The Long Road to the Final AMP Rule

AMP is used to calculate a manufacturer's Medicaid rebate. AMP was first passed into law as part of the Deficit Reduction Act of 2005. CMS's first effort to create implementing regulations for the law was immediately challenged in court by the National Community Pharmacists Association ("NCPA") and enjoined. The statute was then further refined in reaction to the court ruling and NCPA pressure in the Affordable Care Act. Now, almost 11 years after Congress sought to move Medicaid away from the average wholesale price regime, CMS has once again issued implementing regulations.

Bona Fide Service Fees

One question that arises in calculating AMP and a drug's best price is how to account for fees that manufacturers pay to wholesalers and other purchasers. The ACA provides that a drug's AMP calculation should not take into account certain types of fees, including "bona fide service fees," as well as other payments made by manufacturers to purchasers (e.g., reimbursement by manufacturers for recalled, damaged, expired, or otherwise unsalable returned goods). Examples of bona fide service fees include distribution service fees, inventory management fees, product stocking allowances, and fees associated with administrative service agreements and patient care programs (such as medication compliance programs and patient education programs.)

There has been significant controversy and inconsistent price reporting treatment of service fees by manufacturers. Some manufacturers historically accounted for administrative service fees as "bona fide service fees" excluded from AMP, while others accounted for these fees as "discounts" included in AMP. The controversy erupted into the Streck litigation that remains pending in Philadelphia federal court. While a lower AMP may reduce a manufacturer's Medicaid rebate, it also often reduces the reported Average Sales Price and other reported price metrics, creating a mixed bag of conflicting financial incentives. It is likely the case that higher reported AMP prices increase a manufacturer's rebate, so CMS was inclined to favor a definition that required manufacturers to treat these price concessions as fees, not discounts.

CMS's definition of bona fide services has a long and tortured history which we discussed here in the context of the 2012 Proposed Rule. One recurring issue has been the scope of the definition – specifically, whether bona fide service fees include fees paid to any type of entity or whether they apply only to a narrow subset of entities. In its 2012 Proposed Rule, CMS took the latter approach by defining bona fide services as only fees paid "by a manufacturer to a wholesaler or retail community pharmacy." CMS received numerous comments on this limited definition. In the AMP Final Rule, CMS reverses course and broadens the definition to include fees paid to "an entity." In making this change, CMS notes that it does not believe Congress intended to limit the definition of bona fide services fees to only wholesalers and retail community pharmacies.

The AMP Final Rule also addresses the four-part test used to determine if a fee is a bona fide service fee. CMS first introduced this four-part test in a 2007 final rule promulgated in response to the Deficit Reduction Act of 2005. Under the four-part test, a fee is a bona fide service if the fee:

  1. represents fair market value;
  2. for a bona fide, itemized service actually performed on behalf of the manufacturer;
  3. that the manufacturer would otherwise perform (or contract for) in the absence of the service arrangement; and
  4. that is not passed on in whole or in part to a client or customer of an entity.

In the AMP Final Rule, CMS changes its policy regarding how manufacturers should determine whether a fee is "passed on" under the fourth prong of the test. This policy change is accomplished by CMS's adoption of an existing policy that applies to the calculation of Average Sales Price ("ASP"). When calculating ASP, manufacturers are allowed to presume, in the absence of evidence or notice to the contrary, that the fee paid is not passed on. CMS has now adopted this approach in the AMP context. Therefore, if a manufacturer has determined that a fee paid meets the other elements of the definition of bona fide service fee, then the manufacturer may presume, in the absence of any evidence or notice to the contrary, that the fee paid is not passed on to a client or customer of any entity.

The AMP Final Rule does not, however, provide any further guidance about which specific services are considered bona fide service fees. CMS also declined to provide substantive guidance on how to calculate the fair market value of a bona fide service fee. CMS did, however, state that any documentation can be used to demonstrate fair market value as long as the documentation clarifies the methodologies or factors the manufacturer used in making its fair market value determination and the manufacturer maintains adequate documentation supporting its determination.

The net result of the lack of CMS guidance may be yet another windfall to the consulting industry as manufacturers retain experts to advise them concerning the 'fair market value' of various wholesaler services that historically were performed at no charge. This calculation of fair market value is an artificial exercise that is the product of a regulatory system, not an actual matter of economics or financial accounting, as wholesalers historically treated the administrative service fees received from manufacturers as discounts, not fees.

Bundled Services

When calculating AMP, manufacturers must take into account the discounts they provide in a "bundled sale." Bundled sales are sales where the rebate, discount or price concession is "conditioned" upon additional purchase requirements. In its proposed rule, CMS sought to revise the bundled sale definition by adding the following underlined text:

The discounts in a bundled sale, including but not limited to those discounts resulting from a contingent arrangement, are allocated proportionally to the total dollar value of the units of all drugs sold under the bundled arrangement.

CMS decided against finalizing the proposed language. The decision came in response to numerous commenters who expressed concern that the proposed language would require manufacturers to allocate non-contingent discounts provided on drugs included in the bundle sale (as well as any contingent discounts on those drugs) across all products in the bundled sale. CMS explains in the commentary to the Final AMP Rule that its proposed language was not intended to revise its policy of allocating the value of the discounts across only the products within the bundled arrangement. CMS further clarifies this issue by providing that when a manufacturer offers discounts on multiple products under a single contract (for example, to minimize the administrative burden of developing several single contracts which offer separate discounts on the multiple products) no bundled sale exists if the following conditions are satisfied:

  1. a discount or price concession is established independently for each product within the contract;
  2. the purchase price under the contract is not contingent upon any other product in the contract or upon some other performance requirement (such as the achievement of market share or inclusion or tier placement on a formulary); and
  3. the discount provided for any product under the contract is no greater than if the product was purchased outside of the contract.

The AMP Final Rule also revises the definition of "bundled sale" by substituting the word "product" instead of "drugs." CMS explains that bundled arrangements can include covered-outpatient drugs (CODs) as well as other product purchases as part of the bundled sale requirement. The substitution therefore clarifies that a discount on drug purchases that is contingent upon sales of non-drug products is considered a bundled sale.

Retail Community Pharmacy

The definition of retail community pharmacy is critical in determining how to calculate AMP, as AMP is defined as the average price paid by (i) wholesalers for drugs distributed to retail community pharmacies; and (ii) retail community pharmacies for drugs purchased directly from the manufacturer. A key issue with this definition is the extent to which specialty pharmacies, home infusion pharmacies, and home health care providers are considered retail community pharmacies.

CMS finalizes its definition of a retail community pharmacy to mean an independent pharmacy, a chain pharmacy, a supermarket pharmacy, or a mass merchandiser pharmacy that is licensed as a pharmacy by the state and that dispenses medications to the general public at retail prices. It excludes from this definition: pharmacies that dispense prescription medications to patients primarily through the mail, nursing home pharmacies, long-term care facility pharmacies, hospital pharmacies, clinics, charitable or not-for-profit pharmacies, government pharmacies, or pharmacy benefit managers.

In the proposed rule, however, CMS sought comments on a proposal that would include "entities that conduct business as a wholesaler or retail community pharmacy," in the definition of retail community pharmacy. CMS's intent was to specifically capture specialty and home infusion pharmacies and home healthcare providers, and it indicated in the proposed rule that this proposed addition is consistent with the statutory language.

CMS did not finalize this proposal, stating that these entities fall within the existing definition so the expansion is not required. CMS's decision not to expand the definition could be seen as backing away from the requirement that all specialty pharmacies, home infusion pharmacies, and home health care providers be included in the definition of "retail community pharmacies." Under the finalized definition, a pharmacy is only considered to fall into this group to the extent that it is an independent pharmacy, a chain pharmacy, a supermarket pharmacy, or a mass merchandiser pharmacy that dispenses medications to the general public at retail prices and is not otherwise excluded from the definition.

Medicaid Reimbursement Based on Actual Acquisition Cost ("AAC")

One of the AMP Final Rule provisions that could have a significant impact on pharmacies is CMS's requirement that state Medicaid programs reimburse pharmacies based on AAC rather than Estimated Acquisition Cost ("EAC"). EAC is the state' best estimate of the prices generally and currently paid by providers for a drug. Reimbursement based on EAC generally relies on Average Wholesale Price ("AWP") or Wholesale Acquisition Price ("WAC"). Citing OIG reports issued in the early 2000s, CMS indicates that AWP-reimbursement is flawed, potentially resulting in increased reimbursement for covered outpatient drugs. Controversy concerning reported AWP prices resulted in more than a decade of litigation, some of which incredibly is still winding its way through state court systems.

CMS defines AAC as the agency's determination of the pharmacy providers' actual prices paid to acquire drug products marketed or sold by specific manufacturers. In determining AAC, states retain flexibility on the appropriate method and can establish AAC based on several benchmarks including NADAC files, AMP, surveys, or even WAC so long as the state can provide data to support a model of reimbursement using WAC prices that is consistent with §447.512(b).

As of the end of 2015, only a handful of states, including Alabama, Colorado, Idaho, Iowa, Louisiana, and Oregon, include AAC as a component in determining ingredient cost. Another subset of states, including Alaska, Delaware, and Nevada, rely on the NADAC files, which would qualify as AAC under CMS's definition (data based on Medicaid Covered Outpatient Prescription Drug Reimbursement Information by State). Therefore, the vast majority of states will need to undergo State Plan Amendments ("SPAs") to convert their current methodology to one based on AAC. These states have until April 1, 2017 to submit and acquire approval from CMS for the SPA.

The transition from AWP to AAC has not always been easy or smooth for states. As we previously blogged, in July 2014, Mississippi attempted to replace its AWP methodology to one based on AAC, resulting in a revolt by Mississippi pharmacies. Mississippi reverted back to AWP pricing after less than 8 weeks.

As evidenced by Mississippi's experience and as noted by commenters, the transition to AAC could impact pharmacies' decisions to participate in Medicaid. CMS downplays this concern, responding that it has no reason to believe that pharmacies will leave the Medicaid program or that patient care will suffer given that several states are already using AAC-based methodologies. However, if Mississippi's experience is any indicator, states are going to have to balance network adequacy concerns in implementing this change.

It is also important to note that states using AAC-based methodologies have dispensing fees that are two to five times higher than those of states with ingredient cost methodologies based on AWP or WAC (compare e.g., AAC-based states: Iowa (dispensing fee of $11.73) and Alabama ($10.64) to non-AAC states: Ohio ($1.80) and Missouri ($4.09)). Several commenters noted that AAC-based ingredient costs methodologies will require states to increase dispensing fees. In response to these and other concerns on the dispensing fee, CMS:

  • Finalizes the replacement of the term "dispensing fee" with "professional dispensing fee" to reinforce its position that the dispensing fees should reflect the pharmacist's professional services and costs associated with ensuring that possession of the appropriate covered outpatient drug is transferred to a Medicaid beneficiary.
  • Reiterates that states must meet the requirement at 1902(a)(30)(A) of the Social Security Act and ensure that reimbursement is consistent with efficiency, economy, and quality of care while assuring sufficient beneficiary access.
  • Requires that states consider both the ingredient cost reimbursement and the professional dispensing fee reimbursement when proposing changes to either or both of these components.

As a result, as the majority of states move to AAC-based ingredient cost methodologies, they will be forced to consider and examine their professional dispensing fees in light of the AAC reimbursement levels. It is likely that we will see professional dispensing fees increase in these states moving to AAC-based methodologies. Here, again, the big winner is likely to be consultants, as many states will hire consultants to conduct new cost of dispensing studies.

The final rule also clarified that the requirement that reimbursement be based off of AAC is limited to Medicaid fee-for-service and is not required for Medicaid managed care organizations. Medicaid managed care organizations retain the flexibility to reimburse drugs' ingredients costs and professional dispensing fees "at the levels necessary to achieve adequate access to a network of providers."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Theresa C. Carnegie
Ellyn Sternfield
Rodney L. Whitlock
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions